Department of Internal Medicine, The University of Texas Medical Branch, Galveston, Texas.
Department of Gastroenterology, The First Affiliated Hospital, Guangxi University of Science and Technology, Guangxi, China.
Am J Physiol Gastrointest Liver Physiol. 2021 Jun 1;320(6):G1093-G1104. doi: 10.1152/ajpgi.00400.2020. Epub 2021 Apr 28.
Constipation and abdominal pain are commonly encountered in opioid-induced bowel dysfunction (OBD). The underlying mechanisms are incompletely understood, and treatments are not satisfactory. As patients with OBD often have fecal retention, we aimed to determine whether fecal retention plays a pathogenic role in the development of constipation and abdominal pain in OBD, and if so to investigate the mechanisms. A rodent model of OBD was established by daily morphine treatment at 10 mg/kg for 7 days. Bowel movements, colonic muscle contractility, visceromotor response to colorectal distention, and cell excitability of colon-projecting dorsal root ganglion neurons were determined in rats fed with normal pellet food, or with clear liquid diet. Morphine treatment (Mor) reduced fecal outputs starting on , and caused fecal retention afterward. Compared with controls, Mor rats demonstrated suppressed muscle contractility, increased neuronal excitability, and visceral hypersensitivity. Expression of cyclooxygenase-2 (COX-2) and nerve growth factor (NGF) was upregulated in the smooth muscle of the distended colon in Mor rats. However, prevention of fecal retention by feeding rats with clear liquid diet blocked upregulation of COX-2 and NGF, restored muscle contractility, and attenuated visceral hypersensitivity in Mor rats. Moreover, inhibition of COX-2 improved smooth muscle function and fecal outputs, whereas anti-NGF antibody administration attenuated visceral hypersensitivity in Mor rats. Morphine-induced fecal retention is an independent pathogenic factor for motility dysfunction and visceral hypersensitivity in rats with OBD. Liquid diet may have therapeutic potential for OBD by preventing fecal retention-induced mechanotranscription of COX-2 and NGF. Our preclinical study shows that fecal retention is a pathogenic factor in opioid-induced bowel dysfunction, as prevention of fecal retention with liquid diet improved motility and attenuated visceral hyperalgesia in morphine-treated animals by blocking expression of cyclooxygenase-2 and nerve growth factor in the colon.
便秘和腹痛是阿片类药物诱导的肠道功能障碍(OBD)中常见的问题。其潜在机制尚不完全清楚,且治疗效果并不令人满意。由于 OBD 患者常伴有粪便潴留,我们旨在确定粪便潴留是否在 OBD 中便秘和腹痛的发展中起致病作用,如果是,则研究其机制。通过每天给予 10mg/kg 的吗啡治疗 7 天来建立 OBD 的啮齿动物模型。在给予正常颗粒饲料或透明液体饮食的大鼠中,测定排便、结肠肌肉收缩性、结直肠扩张的内脏运动反应和投射到结肠的背根神经节神经元的细胞兴奋性。吗啡治疗(Mor)从第 3 天开始减少粪便排出量,并导致随后的粪便潴留。与对照组相比,Mor 大鼠表现出肌肉收缩性抑制、神经元兴奋性增加和内脏敏感性增加。Mor 大鼠扩张结肠的平滑肌中环氧合酶-2(COX-2)和神经生长因子(NGF)的表达上调。然而,通过给予大鼠透明液体饮食预防粪便潴留可阻断 COX-2 和 NGF 的上调,恢复 Mor 大鼠的肌肉收缩性,并减轻内脏敏感性。此外,COX-2 抑制可改善平滑肌功能和粪便排出量,而抗 NGF 抗体给药可减轻 Mor 大鼠的内脏敏感性。吗啡诱导的粪便潴留是 OBD 大鼠运动功能障碍和内脏敏感性的独立致病因素。液体饮食可能通过预防粪便潴留诱导的 COX-2 和 NGF 的机械转录而具有治疗 OBD 的潜力。我们的临床前研究表明,粪便潴留是阿片类药物诱导的肠道功能障碍的一个致病因素,通过液体饮食预防粪便潴留可通过阻断结肠中 COX-2 和神经生长因子的表达来改善吗啡处理动物的运动功能并减轻内脏痛觉过敏。